Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Autism Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Satisfaction Rates Among Parents of Children With Autism in the ED

NCT02675933
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Questionnaire
Behavioral
Lead sponsor
Seton Healthcare Family
Other
Eligibility
2 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 20, 2026, 4:49 PM EDT
Completed No phase listed Observational

Impact of Improving Gastrointestinal Symptoms on Autism Symptoms and Oxidative Stress

NCT02442115
View directory record Official record
Conditions
Autistic Disorder, Constipation, Gastrointestinal Diseases
Interventions
Treatment of Functional Constipation by
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Not applicable Interventional

Pediatric Aquatic Occupational Therapy for Children With Sensory Processing Challenges

NCT06484946
View directory record Official record
Conditions
Sensory Processing Disorder, Autism Spectrum Disorder, ADHD
Interventions
aquatic occupational therapy
Other
Lead sponsor
Kristen Pataki
Other
Eligibility
4 Years to 9 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seven Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 20, 2026, 4:49 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Crisis Interventions for Pediatric Providers - Autism Version

NCT07508436
View directory record Official record
Conditions
Autism, Suicide Prevention
Interventions
Safety Planning Intervention, Crisis Interventions for Pediatric Providers - Autism version (CIPP-A)
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 20, 2026, 4:49 PM EDT
Completed No phase listed Observational

A Repeatability and Reproducibility Study of the EarliPoint™ Device

NCT04860986
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
EarliPoint
Device
Lead sponsor
EarliTec Diagnostics, Inc
Industry
Eligibility
16 Months to 30 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 20, 2026, 4:49 PM EDT
Completed No phase listed Observational

Pediatric Patients With Metabolic or Other Genetic Disorders

NCT02769949
View directory record Official record
Conditions
Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome, Developmental Delay
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 2 Interventional

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

NCT02715115
View directory record Official record
Conditions
Rett Syndrome
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
5 Years to 15 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance

NCT03002363
View directory record Official record
Conditions
Autism
Interventions
Video Modeling Intervention, Placebo Video
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

NCT01227668
View directory record Official record
Conditions
Irritability Associated With Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Dothan, Alabama • Phoenix, Arizona • Costa Mesa, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

Cariprazine Pediatric ASD PK Study

NCT04382885
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Orange, California • Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 20, 2026, 4:49 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism

NCT07590973
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Neurodevelopmental Conditions
Interventions
BlinkLab Dx1, Retrospective Neurodevelopmental Diagnostic Assessment
Diagnostic Test · Behavioral
Lead sponsor
Blinklab Limited
Industry
Eligibility
2 Years to 11 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 20, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)

NCT06866275
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
KZ101, Placebo
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
5 Years to 14 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Orange, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Sep 20, 2026, 4:49 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2006 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

NCT00872898
View directory record Official record
Conditions
Autism
Interventions
Memantine - Extended Release (ER), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 20, 2026, 4:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Access to Tailored Autism Integrated Care Pilot Study

NCT04293627
View directory record Official record
Conditions
Autism Spectrum Disorder, Mental Health Issue
Interventions
ATTAIN
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Open-Label Extension Study

NCT01914393
View directory record Official record
Conditions
Schizophrenia, Autism, Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
35
States / cities
Dothan, Alabama • Downey, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Not applicable Interventional

Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities

NCT03218462
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Dental Anxiety
Interventions
Sensory Adapted Dental Environment (SADE)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

NCT01999894
View directory record Official record
Conditions
Autism, Pediatric Autism
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 20, 2026, 4:49 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Family, Responsibility, Education, Support, and Health for Families With a Child With Autism

NCT05741840
View directory record Official record
Conditions
Autism Spectrum Disorder, Obesity, Childhood, Autism
Interventions
PBT-A, Health Education (HE)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
6 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 20, 2026, 4:49 PM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Sep 20, 2026, 4:49 PM EDT